Ofev Delays IPF Progression Beyond 52 Weeks, Results from TOMORROW Extension Trial Show
Long-term use of Boehringer Ingelheim’s Ofev (nintedanib) prevents disease progression in patients with idiopathic pulmonary fibrosis (IPF), according to the latest results of the TOMORROW trial and its open-label extension. The study, “Long-term treatment of patients with idiopathic pulmonary…